Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
GATA3
GCDFP-15
Mammaglobin
SOX10
triple negative breast cancer
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
28
10
2019
revised:
20
03
2020
accepted:
14
04
2020
pubmed:
19
4
2020
medline:
24
8
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
Confirmation of a breast origin for triple-negative breast cancer (TNBC) is sometimes problematic. The traditional breast markers GATA-binding protein 3 (GATA3), mammaglobin (MGB) and gross cystic disease fluid protein 15 (GCDFP15) have shown limitations in identifying TNBC. Here, we aimed to examine the diagnostic potential of the newly proposed TNBC marker, Sry-related high-mobility-group/HMG box 10 (SOX10). We analysed and compared SOX10 expression with GATA3, MGB and GCDFP15 expression in a test cohort of 1838 invasive breast cancers (IBCs) by using tissue microarrays. The findings from the test cohort were further examined with a validation cohort of 42 TNBCs in whole sections. The overall expression rates of SOX10, GATA3, MGB and GCDFP15 were 6.9%, 83.1%, 47.0%, and 34.8%, respectively. Among the TNBCs within this cohort, the expression rates of SOX10, GATA3, MGB and GCDFP15 were 31.3%, 34.5%, 27.9%, and 25.2%, respectively. SOX10 was strongly associated with TNBC (P < 0.001), whereas all other traditional markers were associated with non-TNBC (P < 0.001 for all). In addition, SOX10 was more correlated to basal-like breast cancer (BLBC) (P = 0.001) than five-marker-negative subtype among the TNBCs. A high expression rate of SOX10 (81%) was confirmed in the validation cohort. Additionally, SOX10 expression was inversely correlated with GATA3 and GCDFP15 expression, so they may complement each other in TNBC detection. The SOX10-GATA3 combination yielded a sensitivity of 60.3% for TNBC detection in the test cohort. SOX10 is a reliable marker for identifying TNBC, and complements GATA3. The SOX10-GATA3 combination may be used as a sensitive TNBC marker.
Substances chimiques
Biomarkers, Tumor
0
GATA3 Transcription Factor
0
GATA3 protein, human
0
Mammaglobin A
0
SOX10 protein, human
0
SOXE Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
936-948Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Lewis GH, Subhawong AP, Nassar H et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am. J. Clin. Pathol. 2011; 135; 587-591.
Ni YB, Tsang JY, Chan SK, Tse GM. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups. Histopathology 2015; 67; 96-105.
Tozbikian GH, Zynger DL. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Hum. Pathol. 2019; 85; 221-227.
Luo MH, Huang YH, Ni YB et al. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. Hum. Pathol. 2013; 44; 1241-1250.
Miettinen M, McCue PA, Sarlomo-Rikala M et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 2014; 38; 13-22.
Ni YB, Tsang JYS, Shao MM et al. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Breast Cancer Res. Treat. 2018; 169; 25-32.
Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am. J. Clin. Pathol. 2007; 127; 103-113.
Fritzsche FR, Thomas A, Winzer KJ et al. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol. Histopathol. 2007; 22; 1221-1230.
Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am. J. Clin. Pathol. 2012; 138; 57-64.
Shaoxian T, Baohua Y, Xiaoli X et al. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. J. Clin. Pathol. 2017; 70; 926-934.
Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol. Biomarkers. Prev. 2008; 17; 365-373.
Yang Y, Lu S, Zeng W, Xie S, Xiao S. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors. Ann. Diagn. Pathol. 2017; 26; 1-5.
Darb-Esfahani S, von Minckwitz G, Denkert C et al. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer 2014; 14; 546.
Cimino-Mathews A, Subhawong AP, Illei PB et al. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum. Pathol. 2013; 44; 1341-1349.
Harbhajanka A, Chahar S, Miskimen K et al. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma. Hum. Pathol. 2018; 80; 163-169.
Krings G, Nystrom M, Mehdi I, Vohra P, Chen YY. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Hum. Pathol. 2014; 45; 2225-2232.
Byrne DJ, Deb S, Takano EA, Fox SB. GATA3 expression in triple-negative breast cancers. Histopathology 2017; 71; 63-71.
Huo L, Zhang J, Gilcrease MZ et al. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 2013; 62; 267-274.
Mohamed A, Gonzalez RS, Lawson D, Wang J, Cohen C. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl. Immunohistochem. Mol. Morphol. 2013; 21; 506-510.
Miettinen M, McCue PA, Sarlomo-Rikala M et al. Sox10-a marker for not only Schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. Am. J. Surg. Pathol. 2015; 39; 826-835.
Al-Zahrani KN, Cook DP, Vanderhyden BC, Sabourin LA. Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. Oncotarget 2018; 9; 33348-33359.
Cimino-Mathews A, Subhawong AP, Elwood H et al. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum. Pathol. 2013; 44; 959-965.
Chiu K, Ionescu DN, Hayes M. Sox10 expression in mammary invasive ductal carcinomas and benign breast tissue. Virchows Arch. 2019; 474; 667-672.
Nelson ER, Sharma R, Argani P, Cimino-Mathews A. Utility of Sox10 labeling in metastatic breast carcinomas. Hum. Pathol. 2017; 67; 205-210.
Ordonez NG. Value of SOX10 immunostaining in tumor diagnosis. Adv. Anat. Pathol. 2013; 20; 275-283.
Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am. J. Surg. Pathol. 2008; 32; 1291-1298.
Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 445-450.
Zhu YT, Jia Y, Hu L et al. Peroxisome-proliferator-activated receptor-binding protein (PBP) is essential for the growth of active Notch4-immortalized mammary epithelial cells by activating SOX10 expression. Biochem. J. 2009; 425; 435-444.
Dravis C, Spike BT, Harrell JC et al. Sox10 regulates stem/progenitor and mesenchymal cell states in mammary epithelial cells. Cell Rep. 2015; 12; 2035-2048.
Laurent E, Begueret H, Bonhomme B et al. SOX10, GATA3, GCDFP15, androgen receptor, and mammaglobin for the differential diagnosis between triple-negative breast cancer and TTF1-negative lung adenocarcinoma. Am. J. Surg. Pathol. 2019; 43; 293-302.
WHO Classification of Tumors Editorial Board ed. World Health Organization classification of tumours of the breast. Lyon: IARC Press, 2019.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 2011; 22; 1736-1747.
Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
Geyer FC, Pareja F, Weigelt B et al. The spectrum of triple-negative breast disease: high- and low-grade lesions. Am. J. Pathol. 2017; 187; 2139-2151.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 2010; 363; 1938-1948.
Ivanov SV, Panaccione A, Nonaka D et al. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br. J. Cancer 2013; 109; 444-451.
Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008; 26; 2568-2581.
Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11; 5678-5685.
Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 2006; 355; 560-569.
Badve S, Dabbs DJ, Schnitt SJ et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011; 24; 157-167.
Huo L, Gong Y, Guo M et al. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin a in triple-negative breast cancer by immunohistochemistry. Histopathology 2015; 67; 245-254.
Asch-Kendrick R, Cimino-Mathews A. The role of GATA3 in breast carcinomas: a review. Hum. Pathol. 2016; 48; 37-47.
Yang C, Zhang L, Sanati S. SOX10 is a sensitive marker for breast and salivary gland adenoid cystic carcinoma: immunohistochemical characterization of adenoid cystic carcinomas. Breast Cancer (Auckl.) 2019; 13; 1178223419842185.